— Patients treated with RGX-202 demonstrate consistent, robustmicrodystrophin expression and functional improvement compared to natural history in Phase I/II portion of AFFINITY DUCHENNE® trial supporting potential approval via the accelerated approval pathway — REGENXBIO continues to enroll patients in the confirmatory trial — First batches intended for commercial supply manufactured at in-house Manufacturing Innovation Center […]

Spreading Shibuya's charm and driving mindset change through a Halloween-themed digital experience transcosmos inc. (Headquarters: Tokyo, Japan; transcosmos) and Future Design Shibuya General Incorporated Association (Future Design Shibuya) will launch “FIND THE HALLOWEEN SHIBUYA,” a Halloween-themed game experience onRoblox, a popular global immersive platform. This initiative is a part of the Shibuya Good Manner Project,

Cyngn (Nasdaq: CYN) is rapidly advancing its position in the industrial automation sector. Through successful deployments with key customers such as Coats, U.S. Continental and G&J Pepsi, this has been an important year for the company. Cyngn's DriveMod Tuggercontinues to prove its versatility and reliability across a wide range of operational environments, driving innovation and

Top prize awarded to trailblazer revolutionizing how we detect and treat diseases Science and engineering research is vital to driving innovation, economic growth and sustainable development, thus fueling progress in Canada. From advancing clean technologies to improving health care and infrastructure, Canadian scientists and engineers develop solutions that address national and global challenges. Their work

(NYSE:ZH),(HKSE:2390), BEIJING, China, Oct. 30, 2025 (GLOBE NEWSWIRE) — Zhihu Inc. (“Zhihu” or the “Company”) (NYSE: ZH; HKEX: 2390), a leading online content community in China, today announced that it will report its unaudited financial results for the quarter ended September 30, 2025 before the U.S. market opens on November 25, 2025. The Company's management

(NasdaqGM:RNAC), FREDERICK, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) — Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to two new employees. On October 27, 2025, the Company issued to one employee an option to purchase an aggregate of 50,000

(NASDAQ:APLS), Generated $459 million in 3Q 2025 revenues, including $178 million in U.S. net product sales Received 152 new patient start forms for EMPAVELI(R) (pegcetacoplan) in the first two months since launch in C3G and primary IC-MPGN Reported EMPAVELI U.S. net product revenue of $27 million, reflecting strong early launch in C3G and primary IC-MPGN

(NASDAQ:UNCY), LOS ALTOS, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that it will present new oxylanthanum carbonate (OLC) data at the American Society of Nephrology (ASN) Kidney Week 2025, which will take place

Zhihu Inc. to Report Third Quarter 2025 Financial Results on November 25, 2025 GlobeNewswire October 30, 2025 BEIJING, China, Oct. 30, 2025 (GLOBE NEWSWIRE) — Zhihu Inc. (“Zhihu” or the “Company”) (NYSE: ZH; HKEX: 2390), a leading online content community in China, today announced that it will report its unaudited financial results for the quarter

Cartesian Therapeutics Announces New Employment Inducement Grants GlobeNewswire October 30, 2025 FREDERICK, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) — Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to two new employees. On October 27, 2025, the Company issued to